» Articles » PMID: 26257302

RACK1 and β-arrestin2 Attenuate Dimerization of PDE4 CAMP Phosphodiesterase PDE4D5

Overview
Journal Cell Signal
Date 2015 Aug 11
PMID 26257302
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

PDE4 family cAMP-selective cyclic nucleotide phosphodiesterases are important in the regulation of cAMP abundance in numerous systems, and thereby play an important role in the regulation of PKA and EPAC activity and the phosphorylation of CREB. We have used the yeast 2-hybrid system to demonstrate recently that long PDE4 isoforms form homodimers, consistent with data obtained recently by structural studies. The long PDE4 isoform PDE4D5 interacts selectively with β-arrestin2, implicated in the regulation of G-protein-coupled receptors and other cell signaling components, and also with the β-propeller protein RACK1. In the present study, we use 2-hybrid approaches to demonstrate that RACK1 and β-arrestin2 inhibit the dimerization of PDE4D5. We also show that serine-to-alanine mutations at PKA and ERK1/2 phosphorylation sites on PDE4D5 detectably ablate dimerization. Conversely, phospho-mimic serine-to-aspartate mutations at the MK2 and oxidative stress kinase sites ablate dimerization. Analysis of PDE4D5 that is locked into the dimeric configuration by the formation of a trans disulfide bond between Ser261 and Ser602 shows that RACK1 interacts strongly with both the monomeric and dimeric forms, but that β-arrestin2 interacts exclusively with the monomeric form. This is consistent with the concept that β-arrestin2 can preferentially recruit the monomeric, or "open," form of PDE4D5 to β2-adrenergic receptors, where it can regulate cAMP signaling.

Citing Articles

Osthole-Mediated Inhibition of Neurotoxicity Induced by Ropivacaine via Amplification of the Cyclic Adenosine Monophosphate Signaling Pathway.

Wang W, Zhou H, Sun L, Li M, Gao F, Sun A Dose Response. 2022; 20(1):15593258221088092.

PMID: 35392264 PMC: 8980408. DOI: 10.1177/15593258221088092.


Phosphodiesterases Expression during Murine Cardiac Development.

Carvalho T, Cardarelli S, Giorgi M, Lenzi A, Isidori A, Naro F Int J Mol Sci. 2021; 22(5).

PMID: 33807511 PMC: 7961729. DOI: 10.3390/ijms22052593.


Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior.

Bolger G, Smoot L, van Groen T Int J Mol Sci. 2020; 21(16).

PMID: 32784895 PMC: 7460819. DOI: 10.3390/ijms21165704.


Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Baillie G, Tejeda G, Kelly M Nat Rev Drug Discov. 2019; 18(10):770-796.

PMID: 31388135 PMC: 6773486. DOI: 10.1038/s41573-019-0033-4.


Discovery of boron-containing compounds as Aβ aggregation inhibitors and antioxidants for the treatment of Alzheimer's disease.

Lu C, Hu J, Wang Z, Xie S, Pan T, Huang L Medchemcomm. 2018; 9(11):1862-1870.

PMID: 30568754 PMC: 6254047. DOI: 10.1039/c8md00315g.


References
1.
Hoffmann R, Baillie G, MacKenzie S, Yarwood S, Houslay M . The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 1999; 18(4):893-903. PMC: 1171182. DOI: 10.1093/emboj/18.4.893. View

2.
Baillie G, MacKenzie S, Houslay M . Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol. 2001; 60(5):1100-11. DOI: 10.1124/mol.60.5.1100. View

3.
Bruno O, Fedele E, Prickaerts J, Parker L, Canepa E, Brullo C . GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol. 2011; 164(8):2054-63. PMC: 3246667. DOI: 10.1111/j.1476-5381.2011.01524.x. View

4.
Michot C, Le Goff C, Goldenberg A, Abhyankar A, Klein C, Kinning E . Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet. 2012; 90(4):740-5. PMC: 3322219. DOI: 10.1016/j.ajhg.2012.03.003. View

5.
Li X, Vadrevu S, Dunlop A, Day J, Advant N, Troeger J . Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochem J. 2010; 428(1):55-65. DOI: 10.1042/BJ20091672. View